Common diabetes medication slows growth of precancerous esophageal cells, study shows

Wellcome Trust Sanger InstituteSep 16 2024

A common diabetes medication, metformin, slows the growth of precancerous cells in the oesophagus while some metabolic conditions accelerate it, suggests a new study.

Researchers from the Wellcome Sanger Institute discovered that metformin reduced the growth of potentially cancerous cells both in mice and laboratory experiments. The team also found that metabolic conditions such as diabetes and obesity could enhance the growth advantage of these altered cells in human samples.

The findings, recently published in Nature Genetics, highlight the potential role of metformin and overall metabolic health in managing squamous oesophageal cancer risk. Researchers suggest the drug may be beneficial beyond its role in diabetes, though more research is needed.

There are around 9,200 new oesophageal cancer cases diagnosed in the UK each year, about a fifth of these are squamous carcinomas. Patients have a poor survival rate – only around 17 per cent of those in England survive for five years or more¹. These cancers arise from mutated cells present in the oesophagus.

As we age, our body's cells naturally accumulate genetic changes. While most are harmless, some can give cells a growth advantage and may lead to age-related diseases like cancer over time. A gene called PIK3CA is one known to play a major role in cell growth². When mutations occur in this gene, they cause cells to multiply rapidly, and can lead to cancer of the ovary, breast, lung, brain, and oesophagus.

In this new study, partly-funded by Cancer Research UK, researchers from the Wellcome Sanger Institute used experiments in mice, cell cultures and DNA sequencing of human samples to study the evolution of mutations in the oesophagus. They focused on a specific mutation in the PIK3CA gene that can drive aggressive cell growth when altered.

The team observed that cells with these PIK3CA mutations grow faster than normal cells. They also found that a high-fat diet and type 1 diabetes in mice enhanced the growth of cells with PIK3CA mutations. When they looked at human oesophagus samples, they found that overweight individuals had more cells with PIK3CA mutations compared to those at normal weight, indicating that obesity may increase the risk of oesophageal cancer.

Conversely, they discovered that when treated with the antidiabetic drug metformin, the mutant cells lost their growth advantage, both in mice and in lab-grown cells. This effect was seen in mice without diabetes.

Metformin is the most commonly prescribed medication for people with type two diabetes³, used to treat high blood sugar. Previous epidemiological studies have suggested metformin may reduce cancer incidence in diabetic populations⁴, but specific mechanisms of action and which populations may benefit have been little understood. The effect of metformin on the growth of cells carrying PIK3CA mutations opens the door to repurpose this drug to prevent PIK3CA related cancers.

Dr Albert Herms, co-first author of the paper, formerly at the Wellcome Sanger Institute and now at the University of Barcelona, said: “As we age, our bodies accumulate mutated cells. Learning what factors cause cells carrying these cancer-related mutations to grow long before cancer develops opens the door to new prevention strategies. This highlights how advances in cell biology can lead to unexpected health benefits. As we gain more insight into what drives cancer, there are increasing opportunities to repurpose existing drugs, discover new treatments, and explore lifestyle changes that could reduce cancer risk.”

Dr Phil Jones, senior author of the study at the Wellcome Sanger Institute, Professor of Cancer Development at the University of Cambridge and Consultant at Addenbrooke’s Hospital in Cambridge, said: “Our findings show how a common, safe medication like metformin might be used in new ways to prevent cancers related to PIK3CA mutations. This discovery could offer a new tool for cancer prevention, especially in people at higher risk due to metabolic disorders.”

One of the quickest ways to improve cancer outcomes is finding new purposes for existing drugs. This research gives us an important first glimpse into ways in which metformin could be used to prevent oesophageal cancer, though further clinical trials are needed to understand how it should be administered, and which patients could benefit most.  This research, and projects like it, are taking us towards an exciting future where cancer is much more preventable.”

Dr Iain Foulkes, Executive Director of Research and Innovation, Cancer Research UK